Therapeutic choices in patients with Ph-Positive chronic myelogenous leukemia in Mexico in the era of tyrosine kinase inhibitors: stem cell transplantation or tyrosine kinase inhibitors? Fifteen years later
Background: Chronic myelogenous leukemia is a neoplastic proliferation of the granulocytic series. In Mexico, chronic myelogenous leukemia accounts for approximately 10% of all leukemias. Tyrosine-kinase inhibitors are considered front-line therapy in high-income countries, whereas allogeneic hemato...
Saved in:
Main Authors: | Max Robles-Nasta (Author), Daniela Sánchez-Bonilla (Author), Moises M. Gallardo-Pérez (Author), Edgar J. Hernández-Flores (Author), Merittzel A. Montes-Robles (Author), María de L. Pastelín-Martínez (Author), Juan C. Olivares-Gazca (Author), Guillermo J. Ruiz-Delgado (Author), Guillermo J. Ruiz-Argüelles (Author) |
---|---|
Format: | Book |
Published: |
Permanyer,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia
by: Megumi Kikuya, et al.
Published: (2021) -
Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
by: Meike Kaehler, et al.
Published: (2021) -
Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors
by: Michael G. Martin, et al.
Published: (2011) -
Transport of six tyrosine kinase inhibitors: active or passive?
by: Richard J. Honeywell, et al.
Published: (2016) -
Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011)